SequelSEC

Eloxx Pharmaceuticals, Inc. ELOX

Biological Products, (No Diagnostic Substances) · CIK 0001035354 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2025-12-31
Operating income
-$6.44M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Eloxx Pharmaceuticals, Inc. (ELOX) reported revenue of $0 and net income of -$6.00M for the fiscal year ended 2025-12-31. This page shows 4 annual periods of income statement, balance sheet and cash flow figures normalized from Eloxx Pharmaceuticals, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Eloxx Pharmaceuticals, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312014-06-30
Revenue$0$6.36M$0$182.23K
Cost of revenueUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailable
Operating income-$6.44M-$2.47M-$17.29M-$9.15M
Net income-$6.00M-$3.14M-$17.05M-$9.23M
Research & developmentUnavailableUnavailableUnavailable$3.34M
Weighted-average diluted sharesshares 12.35Mshares 3.76Mshares 2.57MUnavailable
Pretax income-$6.00M-$3.14M-$17.05M-$9.23M
Income tax expense$0$0$0$0
Diluted EPS$-0.49$-0.84$-6.63Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailable
General & administrative$3.38M$5.25M$8.69M$3.68M
Selling & marketingUnavailableUnavailableUnavailableUnavailable

Balance

Eloxx Pharmaceuticals, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312014-06-30
Cash & equivalents$4.78M$111.00K$1.13M$6.11M
Total assets$5.27M$2.98M$1.71M$33.33M
Current assets$5.27M$2.98M$1.55M$7.22M
Total liabilities$17.18M$27.31M$24.31M$5.84M
Current liabilities$17.18M$27.31M$22.70M$1.83M
Total equity incl. NCI-$11.91M-$24.34M-$22.60M$27.49M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailable$43.13K
GoodwillUnavailableUnavailableUnavailable$13.90M
Long-term debt$0$0$1.61MUnavailable
Accounts payable$2.71M$5.35M$5.70M$901.18K

Cash flow

Eloxx Pharmaceuticals, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312014-06-30
Operating cash flow-$6.33M-$4.72M-$14.34M-$4.87M
Capital expendituresUnavailableUnavailableUnavailable$3.19K
Investing cash flow$1.00K$38.00K$309.00K$646.94K
Financing cash flow$11.00M$3.44M-$4.08M$8.73M
Net change in cash$4.68M-$1.24M-$18.11M$4.51M
Stock-based compensation$235.00K$541.00K$1.96M$1.30M
Common dividends paidUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailable$349.66K

Derived

Eloxx Pharmaceuticals, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312014-06-30
Free cash flowUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailable-38.8%Unavailable-5019.9%
FCF marginUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailable8.5%Unavailable711.9%
Current ratio0.31x0.11x0.07x3.96x
Revenue YoY growth-100.0%UnavailableUnavailableUnavailable
Net marginUnavailable-49.4%Unavailable-5062.4%
R&D / revenueUnavailableUnavailableUnavailable1832.1%
CapEx / revenueUnavailableUnavailableUnavailable1.8%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ELOX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-03-17View SEC filing
10-Q · Filed 2023-11-13View SEC filing
10-Q · Filed 2023-08-11View SEC filing
10-Q · Filed 2023-05-12View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.